Akeso
Tracked across 3 events · 46 articles · First seen May 25, 2026 · Last active Aug 10, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Akeso received NMPA approval for Gumokimab, strengthening its autoimmune disease portfolio and global competitiveness. This approval is a significant milestone for the company, enhancing its market position and offering a new treatment option for psoriasis patients.
Jun 12, 2026 · 7 articles
Tech
Akeso announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) evaluating AK146D1, its internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate (bsADC), in combination with ivonescimab, its PD-1/VEGF bispecific antibody, for…
Impact: Akeso is the developer and sponsor of the Phase II study, and this milestone advances its IO2.0 + ADC2.0 strategy. The company's pipeline and clinical progress are central to its valuation and growth prospects.
Aug 10, 2026 · 6 articles
Tech
Impact: Akeso announced that over 40 clinical studies of its oncology portfolio, including data on cadonilimab and ivonescimab, were presented at the 2026 ASCO Annual Meeting, with one Late-Breaking Abstract selected for a Plenary Session.
May 25, 2026 · 33 articles
80
Akeso dosed first patientAkeso Doses First Patient...
ERGEN INTELLIGENCE
Track Akeso live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard